ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

作者：Marcus O. Butler, Caroline Robert, Sylvie Négrier, G.K. In, John Walker, Ivana Krajsová, Victoria Atkinson, Johan Hansson, Ellen Kapiteijn, Carmen Loquai, Heather M. Shaw, Tina Cheng, Sandrine Mansard, Jean‐Jacques Grob, Massimo Guidoboni, Minal Mehta, Paolo A. Ascierto, Adi Diab · 发表于：Annals of Oncology · 年份：2019 · DOI：10.1093/annonc/mdz255.061 · 被引用次数：4 · 研究领域：Immunotherapy and Immune Responses、Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research